BioNTech, a COVID-19 vaccine maker, secured up to $145 million in funding from CEPI to establish a production network in African countries for mRNA-based shots. The partnership aims to enhance local research, development, and manufacturing capacities in Africa, with CEPI supporting BioNTech in expanding the manufacturing facility in Rwanda. CEPI also awarded $6.5 million to support phase 2 clinical trials of the MVA-BN nonreplicating vaccine in children in endemic regions. Bavarian Nordic and CEPI plan to advance an mpox vaccine for African children, focusing on addressing cases and deaths in the ongoing outbreak in the DR Congo.
“CEPI has awarded $6.5 million to support phase 2 clinical trials of the MVA-BN nonreplicating vaccine in children ages 2 to 12 as compared to adults. The study will enroll 460 people in endemic regions” https://t.co/QC2Wg1BDC4
Bavarian Nordic, CEPI announce plan to advance mpox vaccine for African children Children have accounted for the major portion of cases and deaths in an ongoing mpox outbreak in the DR Congo. https://t.co/SQCQU9GG4p https://t.co/i5td6HzbJM
BioNTech, flush with $145M from CEPI, looks to expand mRNA vaccine production in Africa https://t.co/dETdEFBac9
"BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa...BioNTech and CEPI commit to contributing to enabling equitable access, including affordable pricing to select vaccines… https://t.co/tAEYuNOGVJ
BioNTech expands its partnership w/ @CEPIvaccines to work on strengthening Africa's mRNA vaccine ecosystem. CEPI will fund up to $145M to support BioNTech in broadening the scope of the manufacturing facility in Rwanda. https://t.co/bRH7svhOJY https://t.co/qrDupySA6P
COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots. https://t.co/lwmFHG2Wdk https://t.co/lwmFHG2Wdk